Highlights from our recent pharmacoepidemiology work

This page features selected Analysis Group material, including recent work related to pharmacoepidemiology.

Presence at ICPE 2023

• Our health care consultants will present their work through a symposium, podium presentation, and six research posters at ICPE 2023. We are a proud gold sponsor of this conference. Please see topics below and our ICPE 2023 Presentation Guide for full details.
• Symposium: Bias Introduced by COVID-19 Related Healthcare Disruptions in Safety and Effectiveness Studies: Proposing Methodological Solutions – Analysis Group will present with speakers from GSK, LSHTM, and the European Medicines Agency
• Podium Presentation: Likelihood of Antimicrobial Resistance in Urinary E. coli Isolates Comparing Female Patients with Recurrent Versus Non-recurrent Uncomplicated Urinary Tract Infection in the US
• Research Posters: We will have six research posters. Topics include:
  • Post-Emergency Use Authorization (EUA) Active Safety Surveillance Study among Individuals in the Veterans Affairs Health System Receiving Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) Vaccine
  • Validation of Real-World Case Definitions for COVID-19 Diagnosis and Severe COVID-19 Illness Among Patients Infected with SARS-CoV-2: Translation of Clinical Trial Definitions to Real-World Settings
  • Development of a Risk Categorization Framework to Quantify Antimicrobial Resistance Risk in Female Patients with Uncomplicated Urinary Tract Infection
  • Identifying Cytokine Release Syndrome in Retrospective Databases: A Performance Assessment of a Claims-Based Algorithm
  • Comparative Effectiveness of Pegcetacoplan (PEG) Versus Ravulizumab (RAV) and Eculizumab (ECU) in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): A Matching-Adjusted Indirect Comparison
  • Development and Validation of a Claims-Based Definitional Algorithm for Moderate Asthma Exacerbations

• In related news, Vice President Marianne Cunnington has been elected to the board of the International Society for Pharmacoepidemiology (ISPE).

Highlights in Drug Safety Epidemiology

• Analysis Group and Pfizer Present Interim Data on COVID-19 Vaccine Safety Surveillance Program of US Veterans Health Administration Patients
• The Acute Effects of Azithromycin Use on Cardiovascular Mortality as Compared with Amoxicillin-Clavulanate in US Veterans
• Long-Term Effectiveness and Safety of Dutasteride versus Finasteride in Patients with Male Androgenic Alopecia in South Korea: A Multicentre Chart Review Study
• Suicidal Ideation and Attempts in the US Among Stimulant-Treated, Non-Stimulant-Treated, and Untreated Patients with a Diagnosis of Attention-Deficit/Hyperactivity Disorder

Highlights in Regulatory Real-World Evidence (RWE)

• Analysis Group Announces Real-World Evidence Study Supported Blueprint Medicines’ Label Expansion of AYVAKYT® (avapritinib) to Advanced Systemic Mastocytosis in the EU
• Analysis Group’s Real-World Data Study Supports FDA’s Recent ExkivityTM (Mobocertinib) Approval
• Analysis Group Research Sheds Light on Regulatory Real-World Evidence in Successful Oncology Product Approvals

Highlights in Patient-Reported Outcome (PRO) Studies

• A New “Gold Standard”? How Digital Health Technologies Can Be Used to Monitor Patient Progress via PROs
• Patient-Reported Outcomes of Upadacitinib Versus Abatacept in Patients with Rheumatoid Arthritis and an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: 12- And 24-Week Results of A Phase 3 Trial
• Analysis Group Team’s Study Comparing Patient-Reported Outcomes of Psoriasis Therapies Provides Data Critical to Successful Regulatory Submissions

Highlights in Artificial Intelligence/Machine Learning

• Profiling Disease and Economic Burden in CRSwNP Using Machine Learning
• Identifying Individuals with Undiagnosed Post-Traumatic Stress Disorder in a Large United States Civilian Population – A Machine Learning Approach
• Deterioration of Health-Related Quality of Life After Withdrawal of Risankizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: A Machine Learning Predictive Model

Compendium of Published Research and Presentations

• Epidemiology, Health Economics, and Outcomes Research: Published Research and Presentations

Click here to learn more about our work. Access our career opportunities here.

 

Contact:

Mei Sheng Duh, MPH, ScD
Managing Principal and Chief Epidemiologist
mei.duh@analysisgroup.com

View Profile